Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2010 (2010), Article ID 835680, 8 pages
http://dx.doi.org/10.1155/2010/835680
Review Article

Molecular Mechanisms of Resistance to Tumour Anti-Angiogenic Strategies

Institute of Developmental Biology and Cancer UMR 6543, University of Nice Sophia Antipolis, CNRS, Centre Antoine Lacassagne, 06189 Nice, France

Received 16 November 2009; Accepted 5 January 2010

Academic Editor: Arkadiusz Dudek

Copyright © 2010 Renaud Grépin and Gilles Pagès. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [48 citations]

The following is the list of published articles that have cited the current article.

  • Michael P. Lisanti, Ubaldo E. Martinez-Outschoorn, Barbara Chiavarina, Stephanos Pavlides, Diana Whitaker-Menezes, Aristotelis Tsirigos, Agnieszka Witkiewicz, Zhao Lin, Renee Balliet, Anthony Howell, and Federica Sotgia, “Understanding the "lethal" drivers of tumor-stroma co-evolution: Emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy in the tumor micro-environment,” Cancer Biology and Therapy, vol. 10, no. 6, pp. 537–542, 2010. View at Publisher · View at Google Scholar
  • Kristi D. Lynn, Christina L. Roland, and Rolf A. Brekken, “VEGF and pleiotrophin modulate the immune profile of breast cancer,” Cancers, vol. 2, no. 2, pp. 970–988, 2010. View at Publisher · View at Google Scholar
  • Ubaldo E. Martinez-Outschoorn, Diana Whitaker-Menezes, Stephanos Pavlides, Barbara Chiavarina, Gloria Bonuccelli, Casey Trimmer, Aristotelis Tsirigos, Gemma Migneco, Agnieszka K. Witkiewicz, Renee Balliet, Isabelle Mercier, Chengwang Wang, Neal Flomenberg, Anthony Howell, Zhao Lin, Jaime Caro, Richard G. Pestell, Federica Sotgia, and Michael P. Lisanti, “The autophagic tumor stroma model of cancer or "battery-operated tumor growth": A simple solution to the autophagy paradox,” Cell Cycle, vol. 9, no. 21, pp. 4297–4306, 2010. View at Publisher · View at Google Scholar
  • Domenico Ribatti, “Novel angiogenesis inhibitors: Addressing the issue of redundancy in the angiogenic signaling pathway,” Cancer Treatment Reviews, vol. 37, no. 5, pp. 344–352, 2011. View at Publisher · View at Google Scholar
  • Ivan Perez-Diaz, Carolina Guzman, Jesus Alberto Olivares-Reyes, Teresa Ramirez, Gabriela Gutierrez-Reyes, Marcia Hiriart, and Guillermo Robles-Diaz, “Evidence of an Intracellular Angiotensin-Generating System and Non-AT(1), Non-AT(2) Binding Site in a Human Pancreatic Cell Line,” Pancreas, vol. 40, no. 5, pp. 701–707, 2011. View at Publisher · View at Google Scholar
  • Camillo Porta, Paolo Pedrazzoli, and Chiara Paglino, “Is immunotherapy re-entering the kidney cancer arena from the back door? Considerations from the Phase I/II study of siltuximab,” Immunotherapy, vol. 3, no. 4, pp. 487–490, 2011. View at Publisher · View at Google Scholar
  • Ezia Bello, Gennaro Colella, Valentina Scarlato, Paolo Oliva, Alexander Berndt, Giovanni Valbusa, Sonia Colombo Serra, Maurizio D'Incalci, Ennio Cavalletti, Raffaella Giavazzi, Giovanna Damia, and Gabriella Camboni, “E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models,” Cancer Research, vol. 71, no. 4, pp. 1396–1405, 2011. View at Publisher · View at Google Scholar
  • Keith M. Stantz, Minsong Cao, Ning Cao, Yun Liang, and Kathy D. Miller, “Monitoring the Longitudinal Intra-tumor Physiological Impulse Response to VEGFR2 Blockade in Breast Tumors Using DCE-CT,” Molecular Imaging and Biology, vol. 13, no. 6, pp. 1183–1195, 2011. View at Publisher · View at Google Scholar
  • D. Y. Heng, M. J. MacKenzie, U. N. Vaishampayan, G. A. Bjarnason, J. J. Knox, M. H. Tan, L. Wood, Y. Wang, C. Kollmannsberger, S. North, F. Donskov, B. I. Rini, and T. K. Choueiri, “Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy,” Annals of Oncology, vol. 23, no. 6, pp. 1549–1555, 2011. View at Publisher · View at Google Scholar
  • Jun Cai, Song Han, Ruan Qing, Daiqing Liao, Brian Law, and Michael E. Boulton, “In pursuit of new anti-angiogenic therapies for cancer treatment,” Frontiers in Bioscience-Landmark, vol. 16, pp. 803–814, 2011. View at Publisher · View at Google Scholar
  • Xavier Descombes, Franck Plouraboue, Abdelhakim El Boustani, Caroline Fonta, Geraldine Leduc, Raphael Serduc, and Timm Weitkamp, “Brain tumor vascular network segmentation from micro-tomography,” Proceedings - International Symposium on Biomedical Imaging, pp. 1113–1116, 2011. View at Publisher · View at Google Scholar
  • W Ketchart, K M Smith, T Krupka, B M Wittmann, Y Hu, P A Rayman, Y Q Doughman, J M Albert, X Bai, J H Finke, Y Xu, A A Exner, and M M Montano, “Inhibition of metastasis by HEXIM1 through effects on cell invasion and angiogenesis,” Oncogene, vol. 32, no. 33, pp. 3829–3839, 2012. View at Publisher · View at Google Scholar
  • Shaad E. Abdullah, and Roman Perez-Soler, “Mechanisms of resistance to vascular endothelial growth factor blockade,” Cancer, vol. 118, no. 14, pp. 3455–3467, 2012. View at Publisher · View at Google Scholar
  • Bryan T. Oronsky, Jan J. Scicinski, Tony Reid, and Susan Knox, “Beyond Antiangiogenesis: Vascular Modulation as an Anticancer Therapy-A Review,” Translational Oncology, vol. 5, no. 3, pp. 133–140, 2012. View at Publisher · View at Google Scholar
  • Sofia Bellou, Evdoxia Karali, Eleni Bagli, Nawaf Al-Maharik, Lucia Morbidelli, Marina Ziche, Herman Adlercreutz, Carol Murphy, and Theodore Fotsis, “The isoflavone metabolite 6-methoxyequol inhibits angiogenesis and suppresses tumor growth,” Molecular Cancer, vol. 11, 2012. View at Publisher · View at Google Scholar
  • E Kim, K-W Cho, J H Park, C-W Park, D Lee, E Lee, D J Kim, K J Kim, S H Yoon, Y Park, S Cho, S Jang, B-C Park, S-W Chi, S H Yoo, M H Jang, H N Kim, E Kim, K Jo, and Y W Park, “Identification of a pivotal endocytosis motif in c-Met and selective modulation of HGF-dependent aggressiveness of cancer using the 16-mer endocytic peptide,” Oncogene, vol. 32, no. 8, pp. 1018–1029, 2012. View at Publisher · View at Google Scholar
  • Kihito Hada, Atsushi Suda, Kohsuke Asoh, Takuo Tsukuda, Masami Hasegawa, Yasuko Sato, Kotaro Ogawa, Shino Kuramoto, Yuko Aoki, Nobuo Shimma, Tsutomu Ishikawa, and Hiroshi Koyano, “Angiogenesis inhibitors identified by cell-based high-throughput screening: Synthesis, structure-activity relationships and biological evaluation of 3-[(E)-styryl]benzamides that specifically inhibit endothelial cell proliferation,” Bioorganic & Medicinal Chemistry, vol. 20, no. 4, pp. 1442–1460, 2012. View at Publisher · View at Google Scholar
  • Alexandra Eichten, Alexander P. Adler, Blerta Cooper, Jennifer Griffith, Yi Wei, George D. Yancopoulos, Hsin Chieh Lin, and Gavin Thurston, “Rapid decrease in tumor perfusion following VEGF blockade predicts long-term tumor growth inhibition in preclinical tumor models,” Angiogenesis, vol. 16, no. 2, pp. 429–441, 2012. View at Publisher · View at Google Scholar
  • Y Xi, Y Wei, B Sennino, A Ulsamer, I Kwan, A N Brumwell, K Tan, M K Aghi, D M McDonald, D M Jablons, and H A Chapman, “Identification of pY654-β-catenin as a critical co-factor in hypoxia-inducible factor-1α signaling and tumor responses to hypoxia,” Oncogene, vol. 32, no. 42, pp. 5048–5057, 2012. View at Publisher · View at Google Scholar
  • Tanmayi P. Mankame, and Mark W. Lingen, “The RB Tumor Suppressor Positively Regulates Transcription of the Anti-angiogenic Protein NOL7,” Neoplasia, vol. 14, no. 12, pp. 1213–+, 2012. View at Publisher · View at Google Scholar
  • Wen Lu, Bingling Dai, Weina Ma, and Yanmin Zhang, “A novel taspine analog, HMQ1611, inhibits growth of non-small cell lung cancer by inhibiting angiogenesis,” Oncology Letters, vol. 4, no. 5, pp. 1109–1113, 2012. View at Publisher · View at Google Scholar
  • John Moroney, Siqing Fu, Stacy Moulder, Gerald Falchook, Thorunn Helgason, Charles Levenback, David Hong, Aung Naing, Jennifer Wheler, and Razelle Kurzrock, “Phase I Study of the Antiangiogenic Antibody Bevacizumab and the mTOR/Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin: Tolerance and Biological Activity,” Clinical Cancer Research, vol. 18, no. 20, pp. 5796–5805, 2012. View at Publisher · View at Google Scholar
  • Xiangyu Yang, Ewa Mrozek, Maryam Lustberg, Guang Jia, Steffen Sammet, Christina Sammet, Charles Shapiro, and Michael V. Knopp, “Microcirculatory fraction (MCFI) as a potential imaging marker for tumor heterogeneity in breast cancer,” Magnetic Resonance Imaging, vol. 30, no. 8, pp. 1059–1067, 2012. View at Publisher · View at Google Scholar
  • W Wang, Y Ma, J Li, H-S Shi, L-Q Wang, F-C Guo, J Zhang, D Li, B-H Mo, F Wen, T Liu, Y-T Liu, Y-S Wang, and Y-Q Wei, “Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency,” Gene Therapy, 2013. View at Publisher · View at Google Scholar
  • S. Bellou, G. Pentheroudakis, C. Murphy, and T. Fotsis, “Anti-angiogenesis in cancer therapy: Hercules and hydra,” Cancer Letters, 2013. View at Publisher · View at Google Scholar
  • Thomas J. Herzog, and Robert L. Coleman, “Investigational agents in development for the treatment of ovarian cancer,” Investigational New Drugs, vol. 31, no. 1, pp. 213–229, 2013. View at Publisher · View at Google Scholar
  • I‑Ju Yeh, Ndiya Ogba, Heather Bensigner, Scott M. Welford, and Monica M. Montano, “HEXIM1 down-regulates hypoxia-inducible factor-1α protein stability,” Biochemical Journal, vol. 456, no. 2, pp. 195–204, 2013. View at Publisher · View at Google Scholar
  • C. Athena Aktipis, and Randolph M. Nesse, “Evolutionary foundations for cancer biology,” Evolutionary Applications, vol. 6, no. 1, pp. 144–159, 2013. View at Publisher · View at Google Scholar
  • Mike F. Burbridge, Jean A. Boutin, Alain Pierre, John A. Hickman, Gilles Ferry, Valerie Cattan, Anne Jacquet-Bescond, Paolo M. Comoglio, Jean-Claude Ortuno, Imre Fejes, Brian P. Lockhart, Alex Cordi, Celine J. Bossard, Carine Saunier, Alain Bruno, Francois Bouzom, Francisco H. Cruzalegui, Stephane Depil, Stephane Leonce, and Georges Da Violante, “S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab,” Molecular Cancer Therapeutics, vol. 12, no. 9, pp. 1749–1762, 2013. View at Publisher · View at Google Scholar
  • Martin H. Voss, James J. Hsieh, and Robert J. Motzer, “Novel Approaches Targeting the Vascular Endothelial Growth Factor Axis in Renal Cell Carcinoma,” The Cancer Journal, vol. 19, no. 4, pp. 299–306, 2013. View at Publisher · View at Google Scholar
  • Emiko Maeda, Kiyohito Kato, Joji Tani, Hirohito Yoneyama, Teppei Sakamoto, Hisakazu Iwama, Tsutomu Masaki, Kei Nomura, Hisaaki Miyoshi, Takako Nomura, Hideki Kobara, Hirohito Mori, Shima Mimura, Koji Fujita, Asahiro Morishita, and Gong Jian, “Expression of angiogenic factors in hepatocarcinogenesis: Identification by antibody arrays,” Oncology Reports, vol. 30, no. 5, pp. 2476–2480, 2013. View at Publisher · View at Google Scholar
  • Maria Felice Brizzi, and Paola Defilippi, “Dll4/Notch1 signaling from tip/stalk endothelial cell specification to stroma-dependent lung tumor inhibition: A flavor of Dll4/Notch1 pleiotropy in tumor cell biology,” Translational Lung Cancer Research, vol. 2, no. 6, pp. 466–469, 2013. View at Publisher · View at Google Scholar
  • Haneen Nur, Luigia Rao, Maria Antonia Frassanito, Hendrik De Raeve, Domenico Ribatti, Josué Kunjom Mfopou, Els Van Valckenborgh, Elke De Bruyne, Angelo Vacca, Karin Vanderkerken, and Eline Menu, “Stimulation of invariant natural killer T cells by α-Galactosylceramide activates the JAK-STAT pathway in endothelial cells and reduces angiogenesis in the 5T33 multiple myeloma model,” British Journal of Haematology, 2014. View at Publisher · View at Google Scholar
  • Cristiano Ferrario, and Gerald Batist, “Advances in the approach to novel drug clinical development for breast cancer,” Expert Opinion on Drug Discovery, pp. 1–22, 2014. View at Publisher · View at Google Scholar
  • Lei Pan, Ruiqiang Weng, Jinxia Zhang, Jinsheng Wang, Yong Tang, and Ning Deng, “Immune Response of the VEGF/bFGF Complex Peptide Vaccine and Function of Immune Antibodies in Inhibiting Migration of HUVEC Cells and Proliferation of Cancer Cells,” International Journal of Peptide Research and Therapeutics, vol. 20, no. 4, pp. 565–574, 2014. View at Publisher · View at Google Scholar
  • Masamitsu Kanada, Jinyan Zhang, Libo Yan, Takashi Sakurai, and Susumu Terakawa, “Endothelial cell-initiated extravasation of cancer cells visualized in zebrafish,” PeerJ, vol. 2, pp. e688, 2014. View at Publisher · View at Google Scholar
  • David H. Jensen, Marianne H. Therkildsen, and Erik Dabelsteen, “A reverse Warburg metabolism in oral squamous cell carcinoma is not dependent upon myofibroblasts,” Journal of Oral Pathology & Medicine, 2014. View at Publisher · View at Google Scholar
  • Qing Zhang, Xuejun Lao, Jianhua Huang, Zhongsong Zhu, Lei Pang, Yong Tang, Qifang Song, Jiangfang Huang, Jie Deng, Ning Deng, Qin Yang, Aditi M. Sengupta, and Likuan Xiong, “Soluble production and function of vascular endothelial growth factor/basic fibroblast growth factor complex peptide,” Biotechnology Progress, 2014. View at Publisher · View at Google Scholar
  • Bingling Dai, Junpeng Qi, Rui Liu, Jie Zhang, Yingzhuan Zhan, and Yanmin Zhang, “A novel compound T7 (N-{4′-[(1E)-N-hydroxyethanimidoyl]-3′,5,6-trimethoxybiphenyl-3-yl}-N′-[4-(3-morpholin-4-ylpropoxy)phenyl]urea) screened by tissue angiogenesis model and its activity evaluation on anti-angiogenesis,” Phytomedicine, vol. 21, no. 12, pp. 1675–1683, 2014. View at Publisher · View at Google Scholar
  • E. Jubeli, N. Yagoubi, F. Pascale, L. Bédouet, K. Slimani, D. Labarre, J.P. Saint-Maurice, A. Laurent, and L. Moine, “Embolization biomaterial reinforced with nanotechnology for an in-situ release of anti-angiogenic agent in the treatment of hyper-vascularized tumors and arteriovenous malformations,” European Journal of Pharmaceutics and Biopharmaceutics, 2015. View at Publisher · View at Google Scholar
  • Tsunaki Hongu, Yuji Funakoshi, Shigetomo Fukuhara, Teruhiko Suzuki, Susumu Sakimoto, Nobuyuki Takakura, Masatsugu Ema, Satoru Takahashi, Susumu Itoh, Mitsuyasu Kato, Hiroshi Hasegawa, Naoki Mochizuki, and Yasunori Kanaho, “Arf6 regulates tumour angiogenesis and growth through HGF-induced endothelial β1 integrin recycling,” Nature Communications, vol. 6, pp. 7925, 2015. View at Publisher · View at Google Scholar
  • Angelika Kaczyńska, and Anna Herman-Antosiewicz, “Combination of lapatinib with isothiocyanates overcomes drug resistance and inhibits migration of HER2 positive breast cancer cells,” Breast Cancer, 2016. View at Publisher · View at Google Scholar
  • Tsunaki Hongu, Yohei Yamauchi, Yuji Funakoshi, Naohiro Katagiri, Norihiko Ohbayashi, and Yasunori Kanaho, “Pathological functions of the small GTPase Arf6 in cancer progression: tumor angiogenesis and metastasis,” Small GTPases, pp. 00–00, 2016. View at Publisher · View at Google Scholar
  • Roger M. Phillips, “Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs,” Cancer Chemotherapy and Pharmacology, 2016. View at Publisher · View at Google Scholar
  • Qi Wang, Shuai Wang, Si-Qiao Sun, Zhi-Hua Cheng, Yang Zhang, Guang Chen, Meng Gu, Hai-Jun Yao, Zhong Wang, Juan Zhou, Yu-Bing Peng, Ming-Xi Xu, Ke Zhang, and Xi-Wei Sun, “The effects of RNA interference mediated VEGF gene silencing on biological behavior of renal cell carcinoma and transplanted renal tumor in nude mice,” Cancer Biomarkers, vol. 16, no. 1, pp. 1–9, 2016. View at Publisher · View at Google Scholar
  • You Zhou, Song Shan, Zhi-Bin Li, Li-Jun Xin, De-Si Pan, Qian-Jiao Yang, Ying-Ping Liu, Xu-Peng Yue, Xiao-Rong Liu, Ji-Zhou Gao, Jin-Wen Zhang, Zhi-Qiang Ning, and Xian-Ping Lu, “CS2164, a novel multi-target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti-tumor potency,” Cancer Science, 2017. View at Publisher · View at Google Scholar
  • Ligang Zhang, Dan He, Jianhua Huang, Yanrui Deng, Ruiqiang Weng, Lei Pan, and Ning Deng, “The Immunogenicity and Immunoprotection of VBP3 Multi-epitope Vaccine Targeting Angiogenesis and Tumor Inhibition in Lung Cancer-Bearing Mice,” International Journal of Peptide Research and Therapeutics, 2017. View at Publisher · View at Google Scholar
  • Michael B Atkins, Elizabeth R Plimack, Igor Puzanov, Mayer N Fishman, David F McDermott, Daniel C Cho, Ulka Vaishampayan, Saby George, Thomas E Olencki, Jamal C Tarazi, Brad Rosbrook, Kathrine C Fernandez, Mariajose Lechuga, and Toni K Choueiri, “Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial,” The Lancet Oncology, 2018. View at Publisher · View at Google Scholar